Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 4261-4272

  Raab, Stefanie ^a,b   Steinbacher, Julia ^a,b   Schmiedel, Benjamin J ^a,b   Kousis, Philaretos C ^a,b   Steinle, Alexander ^c   Jung, Gundram ^a   Grosse Hovest, Ludger ^a   Salih, Helmut R ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HYBRID PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D IMMUNOGLOBULIN G1 FUSION PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D LIGAND; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT; KLRK1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

AMINO ACID SUBSTITUTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; NATURAL KILLER CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; WILD TYPE; BIOSYNTHESIS; BREAST TUMOR; CYTOTOXICITY; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTOR, ERBB-2; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 84907494144     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400872     Document Type: Article

References (39)

1. Sporn, M. B. 1996. The war on cancer. Lancet 347: 1377-1381.
2. Jemal, A., M. M. Center, C. DeSantis, and E. M. Ward. 2010. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 19: 1893-1907.
3. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and M. F. Press. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
4. Lane, H. A., A. B. Motoyama, I. Beuvink, and N. E. Hynes. 2001. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann. Oncol. 12(Suppl. 1): S21-S22.
5. Izumi, Y., L. Xu, E. di Tomaso, D. Fukumura, and R. K. Jain. 2002. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280.
6. Gennari, R., S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, L. Villani, C. Magalotti, N. Gibelli, et al. 2004. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10: 5650-5655.
7. Yamashita-Kashima, Y., S. Iijima, K. Yorozu, K. Furugaki, M. Kurasawa, M. Ohta, and K. Fujimoto-Ouchi. 2011. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 17: 5060-5070.
8. Cardinale, D., A. Colombo, R. Torrisi, M. T. Sandri, M. Civelli, M. Salvatici, G. Lamantia, N. Colombo, S. Cortinovis, M. A. Dessanai, et al. 2010. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28: 3910-3916.
9. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329-339.
10. Seidel, U. J., P. Schlegel, and P. Lang. 2013. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front. Immunol. 4: 76.
11. Adams, G. P., and L. M. Weiner. 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157.
12. Bianchini, G., and L. Gianni. 2014. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 15: e58-e68.
13. Ullrich, E., J. Koch, A. Cerwenka, and A. Steinle. 2013. New prospects on the NKG2D/NKG2DL system for oncology. OncoImmunology 2: e26097.
14. Raulet, D. H., S. Gasser, B. G. Gowen, W. Deng, and H. Jung. 2013. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31: 413-441.
15. de Kruijf, E. M., A. Sajet, J. G. H. van Nes, H. Putter, V. T. H. B. Smit, R. A. Eagle, I. Jafferji, J. Trowsdale, G. J. Liefers, C. J. H. van de Velde, and P. J. K. Kuppen. 2012. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12: 24.
16. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
17. Armour, K. L., M. R. Clark, A. G. Hadley, and L. M. Williamson. 1999. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur. J. Immunol. 29: 2613-2624.
18. Salih, H. R., H. Antropius, F. Gieseke, S. Z. Lutz, L. Kanz, H. G. Rammensee, and A. Steinle. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396.
19. Baltz, K. M., M. Krusch, A. Bringmann, P. Brossart, F. Mayer, M. Kloss, T. Baessler, I. Kumbier, A. Peterfi, S. Kupka, et al. 2007. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 21: 2442-2454.
20. Bowles, J. A., S. Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M. A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al. 2006. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108: 2648-2654.
21. Dall'Ozzo, S., S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault. 2004. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64: 4664-4669.
22. Okita, R., D. Mougiakakos, T. Ando, Y. Mao, D. Sarhan, E. Wennerberg, B. Seliger, A. Lundqvist, K. Mimura, and R. Kiessling. 2012. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chainrelated molecule A and B expression in human breast cancer cell lines. J. Immunol. 188: 2136-2145.
23. Mellor, J. D., M. P. Brown, H. R. Irving, J. R. Zalcberg, and A. Dobrovic. 2013. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 6: 1.
24. Keating, G. M. 2010. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70: 1445-1476.
25. Hudis, C. A. 2007. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357: 39-51.
26. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
27. Spear, P., M. R. Wu, M. L. Sentman, and C. L. Sentman. 2013. NKG2D ligands as therapeutic targets. Cancer Immun. 13: 8.
28. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166.
29. Owen, C., and D. A. Stewart. 2012. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin. Biol. Ther. 12: 343-351.
30. Musolino, A., N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26: 1789-1796.
31. Vivier, E., D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
32. Hilpert, J., L. Grosse-Hovest, F. Grünebach, C. Buechele, T. Nuebling, T. Raum, A. Steinle, and H. R. Salih. 2012. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J. Immunol. 189: 1360-1371.
33. Inoue, M., K. Mimura, S. Izawa, K. Shiraishi, A. Inoue, S. Shiba, M. Watanabe, T. Maruyama, Y. Kawaguchi, S. Inoue, et al. 2012. Expression of MHC class I on breast cancer cells correlates inversely with HER2 expression. OncoImmunology 1: 1104-1110.
34. Bryceson, Y. T., and H. G. Ljunggren. 2008. Tumor cell recognition by the NK cell activating receptor NKG2D. Eur. J. Immunol. 38: 2957-2961.
35. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
36. Bruhns, P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649.
37. Albanesi, M., D. A. Mancardi, F. Jönsson, B. Iannascoli, L. Fiette, J. P. Di Santo, C. A. Lowell, and P. Bruhns. 2013. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122: 3160-3164.
38. Shiokawa, M., T. Takahashi, A. Murakami, S. Kita, M. Ito, K. Sugamura, and N. Ishii. 2010. In vivo assay of human NK-dependent ADCC using NOD/SCID/ gammac(null) (NOG) mice. Biochem. Biophys. Res. Commun. 399: 733-737.
39. Ma, Y., B. R. Lin, B. Lin, S. Hou, W. Z. Qian, J. Li, M. Tan, J. Ma, B. H. Li, H. Wang, et al. 2009. Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol. Sin. 30: 364-371.